Cel-Sci and Ergomed Sign Co-Development and Profit Sharing Agreement for Multikine in HIV/HPV Co-Infected Women with Cervical Dysplasia
CEL-SCI Corporation announced that it has signed a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. for CEL-SCI’s investigational immunotherapy drug Multikine (“Leucocyte Interleukin Inj.”) in HIV/HPV co-infected women with cervical dysplasia. Human Papilloma Virus (HPV) is the most common sexually transmitted disease. HPV is a significant health problem in the HIV infected population as individuals are living longer as a result of greatly improved HIV medications. People living with HIV and others with compromised immunity are more...
View full press release